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ORIGINAL ARTICLE
Transcriptomic effects of adenosine 2A receptor deletion
in healthy and endotoxemic murine myocardium
Kevin J. Ashton1 & Melissa E. Reichelt2 & S. Jamal Mustafa3 & Bunyen Teng3 &
Catherine Ledent4 & Lea M. D. Delbridge5 & Polly A. Hofmann6 & R. Ray Morrison7 &
John P. Headrick8
# Springer Science+Business Media Dordrecht 2016
Abstract Influences of adenosine 2A receptor (A2AR) activity
on the cardiac transcriptome and genesis of endotoxemic myo-
carditis are unclear. We applied transcriptomic profiling (39 K
Affymetrix arrays) to identify A2AR-sensitive molecules, re-
vealed by receptor knockout (KO), in healthy and endotoxemic
hearts. Baseline cardiac function was unaltered and only 37
A2AR-sensitive genes modified by A2AR KO (≥1.2-fold change,
<5 % FDR); the five most induced are Mtr, Ppbp, Chac1, Ctsk
and Cnpy2 and the five most repressed are Hp, Yipf4, Acta1,
Cidec and Map3k2. Few canonical paths were impacted, with
altered Gnb1, Prkar2b, Pde3b and Map3k2 (among others)
implicating modified G protein/cAMP/PKA and cGMP/NOS
signalling. Lipopolysaccharide (LPS; 20 mg/kg) challenge for
24 h modified >4100 transcripts in wild-type (WT) myocardium
(≥1.5-fold change, FDR < 1 %); the most induced are Lcn2
(+590); Saa3 (+516); Serpina3n (+122); Cxcl9 (+101) and
Cxcl1 (+89) and the most repressed are Car3 (−38); Adipoq
(−17); Atgrl1/Aplnr (−14); H19 (−11) and Itga8 (−8).
Canonical responses centred on inflammation, immunity, cell
death and remodelling, with pronounced amplification of toll-
like receptor (TLR) and underlying JAK-STAT, NFκB and
MAPK pathways, and a ‘cardio-depressant’ profile
encompassing suppressed ß-adrenergic, PKA and Ca2+ signal-
ling, electromechanical and mitochondrial function (and major
shifts in transcripts impacting function/injury including Lcn2,
S100a8/S100a9, Icam1/Vcam and Nox2 induction, and Adipoq,
Igf1 and Aplnr repression). Endotoxemic responses were selec-
tively modified by A2AR KO, supporting inflammatory suppres-
sion via A2AR sensitive shifts in regulators of NFκB and JAK-
STAT signalling (IκBζ, IκBα, STAT1, CDKN1a and RRAS2)
without impacting the cardio-depressant gene profile. Data indi-
cate A2ARs exert minor effects in un-stressed myocardium and
selectively suppressNFκBand JAK-STATsignalling and cardiac
injury without influencing cardiac depression in endotoxemia.
Keywords Adenosine . Adenosine 2A receptor .
Anti-inflammatory . Cytokines . Endotoxemic myocarditis .
Gene expression . Inflammation .Microarray . Sepsis
Introduction
Uncontrolled inflammation with sepsis and the systemic inflam-
matory response syndrome induce multiple organ dysfunction,
including cardiac abnormalities key to disease progression and
mortality [1]. Unravelling the complex mechanisms governing
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myocardial injury [1, 2] is not only fundamentally important but
also reveals targets for manipulating outcomes. In this regard,
adenosine 2A receptors (A2ARs)may fulfil a broadly suppressive
role to limit inflammatory injury in multiple tissues [3–6] and
enhance myocardial resistance to ischaemic/hypoxic insult, pre-
senting a potentially useful therapeutic target [3, 7]. In heart, this
G protein-coupled receptor (GPCR) influences coronary tone
and angiogenesis, cardiac contractility, fibroblast growth and fi-
brosis and may mediate protection via ischaemic pre- and post-
conditioning [8–10]. Inflammatory modulation contributes to
this latter cardioprotection [9–11], together with the regulation
of myocyte kinase signals to limit oxidative stress, mitochondrial
dysfunction and cell death [12–14]. However, impacts of the
A2AR on integrated myocardial responses to uncontrolled in-
flammation, and themechanisms underlying such effects, remain
to be elucidated.
While adenosine analogues and A2AR agonists can limit
endotoxemic or septic injury in lung [15, 16], liver [17], brain
[18] and heart [19–21], the roles of intrinsic A2AR activity are
less clear. Receptor deletion fails to modify inflammatory
markers/injury in some studies [22], reportedly worsens
endotoxemic injury in heart [23] and lung [15, 24] and im-
proves survival in models of polymicrobial sepsis [25, 26].
These divergent outcomes may reflect different cell- and
organ-specific effects of A2ARs, for example promoting
inflammasome formation and macrophage-dependent injury
[27], impairing bacterial clearance [25], while activating car-
diac survival signalling and suppressing inflammation [3, 7,
12–14]. Nonetheless, opposing effects of endogenous vs. ex-
ogenous (or amplified endogenous) adenosine are evident
within cell types, for example inhibiting vs. promoting vascu-
lar myocyte NOS activation with inflammation [28]. The
chronicity of receptor activation may also be critical to
tissue-specific responses; while acute or transient increases
in adenosine levels/receptor activity are generally beneficial
(improving tissue perfusion, ischemic/hypoxic tolerance and
reducing cytokines/inflammation), chronic elevations may be
detrimental, exaggerating fibrotic processes via A2BRs in lung
[29] or A2A and A2BRs in liver [30, 31], for example.Whether
acute vs. chronic A2AR activity induces opposing myocardial
outcomes is unknown, though prolonged A2B agonism limits
rather than promotes fibrosis in injured myocardium [32], as
does prolonged A1 agonism [33].
Additional to questions regarding protective vs. deleterious
effects of the A2AR, the evolution of myocardial inflammatory
injury and ‘endotoxemic myocarditis’ itself is complex and
incompletely defined [1, 2]. Effects in non-cardiac tissues in-
volve TLR/CD14-dependent NFκB and MAPK signalling
and interferon/cytokine engagement of the JAK-STAT path
[34–36]. These mechanisms likely participate in heart, with
evidence NFκB and IκB kinase promotes cardiac dysfunction
in sepsis/endotoxemia [37, 38], while JAK-STAT signalling
mediates dysfunction and cell death in myocardial ischemia
[39, 40]. In vivo observations suggest marked expansion of
this signalling in intact myocardium [41, 42], contrasting
in vitro evidence that cardiomyocyte NFκB and IκB kinase
signalling is only transiently LPS responsive [43].
Importantly, these paths are inhibited by A2ARs in other cells,
with exogenous agonism decreasing [44, 45] and A2AR KO
increasing NFκB activity [6]. Nonetheless, these paths can
also promote myocardial stress-resistance and survival under
conditions that include inflammatory cytokine challenge
[46–48]. The molecular underpinnings of endotoxemic myo-
carditis in vivo warrant further investigation, as do the mech-
anisms countering this dysfunction (including A2AR activity).
We thus undertook broad-scale transcriptomic profiling of
hearts fromWTand A2ARKOmice, at baseline and following
endotoxin challenge: shifts in gene expression can shed light
on both functions of the A2AR, and pathogenesis and modu-
lation of endotoxemic myocarditis. There are no prior analy-
ses of transcriptome-wide effects of A2AR activity in myocar-
dium, and relatively few of the in situ cardiac response to
endotoxemia or sepsis [41, 42, 49].
Materials and methods
Animals
All animal procedures conformed to the Guide for the Care
and Use of Laboratory Animals published by the NIH (publi-
cation number 85-25, revised 1996). This project (and proto-
cols for care of animals) was approved by the Animal Care
and Use Committees of St. Jude Children’s Research Hospital
and the University of Tennessee Health Sciences Center. The
A2AR KOmice andWT littermates were obtained from a sub-
colony of the original lines generated and characterized by
Ledent et al. [50]. Analysis of cardiac tissue confirms ablation
of A2AR transcript without compensatory shifts in other aden-
osine receptors (Fig. S1). Mice were bred and maintained on-
site at St. Jude Children’s Research Hospital, with standard
laboratory food and water available ad libitum. Animal geno-
type was confirmed by PCR analysis of tail snips. All animals
were originated from the same breeding series and were
matched for age and weight. Male and female mice were used
with equal representation in each experimental group. Both
A2AR KO and WT littermate mice were randomly allocated
to receive either an intraperitoneal injection of 20 mg/kg LPS
isolated from E. coli (Sigma-Aldrich, St. Louis, MO) or an
equal volume of sterile saline vehicle. Blood was sampled at
12 and 24 h of LPS challenge to assess shifts in blood cell
counts and circulating cytokines/biomarkers, as detailed by us
previously [23]. Mice were monitored for the development of
symptoms of illness or distress (lethargy, piloerection,
hunched posture and/or respiratory distress) during the initial
12 h post-injection and every 4 h thereafter; observation of
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any combination of symptoms prompted immediate euthana-
sia. All efforts were made to minimize animal suffering and
distress. No analgesic or anaesthetic was administered other
than for euthanasia immediately on evidence of illness/
distress.
We initially tested responses to 24 h LPS challenge in both
young (14 week) and old (46–52 weeks) WT and A2AR KO
mice. However, absent overt symptoms of illness/distress,
there was nonetheless significant mortality in aged LPS-
treated mice, as detailed in the “Results” section and in
Supplementary material. Cause of death in older animals
was not determined. As a result of mortality, detailed molec-
ular interrogation of cardiac gene expression (n = 6–8 per
group), together with analyses of cardiac function in isolated
hearts (n = 8–9 per group) and haematological/biomarker as-
sessment (n = 6–9 per group) is necessarily constrained to the
young group of mice.
Langendorff perfusion and tissue sampling
After 24 h of LPS challenge, mice were anaesthetised with
sodium pentobarbital (50 mg/kg intraperitoneally), a thoracot-
omy performed and hearts excised into ice-cold Krebs-
Henseleit solution for Langendorff perfusion, as detailed pre-
viously [23], or sampling of ventricular tissue for RNA prep-
aration. Briefly, for perfusions, the aorta was immediately
cannulated and hearts perfused at 80 mmHg with modified
Krebs-Henseleit solution containing (in mM): NaCl, 120;
NaHCO3, 25; KCl, 4.7; CaCl2, 2.5; MgCl2, 1.2; KH2PO4,
1.2; D-glucose, 15 and EDTA, 0.5. Perfusion fluid was main-
tained at 37 °C and bubbled with a mix of 95 % O2/5 %
CO2 at 37 °C to provide a pH of 7.4. Ventricular function
was monitored via a fluid-filled plastic film balloon in the left
ventricle, connected to a P23 XL pressure transducer (Viggo-
Spectramed, Oxnard, CA, USA). Coronary flow was moni-
tored via a flow-probe in the aortic perfusion line, connected
to a T206 flowmeter (Transonic Systems Inc., Ithaca, NY,
USA). Functional data were recorded at 1 KHz on MacLab
data acquisition system (ADInstruments, Castle Hill,
Australia). Statistical comparisons of cardiovascular
(Table 1) and blood parameters (Figs. 1 and 2) between groups
were made via analysis of variance (ANOVA), with a
Newman-Keuls post hoc test for specific comparisons. A
P < 0.05 was considered indicative of significance in all tests.
RNA preparation and microarray hybridisation
Ventricular tissue was isolated, frozen in liquid N2 and stored
at −80 °C until analysis. Tissue was subsequently homoge-
nized in TRIzol reagent (Invitrogen, Carlsbad, CA) and total
RNA isolated according to manufacturer’s protocol. The RNA
was further treated with 50 U of DNase I (Promega, Madison,
WI) for 15 min at 37 °C and purified on RNeasy spin columns
(Qiagen, Hilden, Germany). Total RNA yield and integrity
were determined spectrophotometrically and via capillary
electrophoresis on a 2100 BioAnalyzer (Agilent, Palo Alto,
CA), respectively.
Microarray experiments were performed at the St. Jude
Hartwell Center Core Facility according to manufacturers’
protocols. Briefly, first- and second-strand complementary
DNA (cDNA) synthesis reactions were performed using the
SuperScript Choice System (Invitrogen, Carlsbad, CA)
followed by in vitro transcription using biotin-labelled
dNTPs (ENZO Diagnos t ics , Farmingda le , NY) .
Complementary RNA (cRNA) samples were fragmented
and individually hybridized to GeneChip® Mouse Genome
430 2.0 microarrays (Affymetrix, Santa Clara, CA). Each mi-
croarray quantified expression of over 39,000 transcripts, in-
cluding full-length mRNA sequences and expressed sequence
tags (ESTs). Following hybridization, microarrays were
washed and stained with streptavidin–phycoerythrin
(Molecular Probes, Eugene, OR) before scanning. Image files
were converted into probe-set data (*.CEL files) via
Affymetrix MAS 5.0 software. Experimental data are accessi-
ble through GEO Series accession number GSE44363 at
http://www.ncbi.nlm.nih.gov/geo.
Microarray data and statistical analyses
Raw expression data were background corrected, normal-
ized and log2 transformed using the Robust Multichip
Average (RMA) method in BioConductor/R [51]. Data
were filtered to include only transcripts detected on ≥3
arrays, with 25,646 transcripts passing this quality criteri-
on (i.e. consistently detected in cardiac tissue). Log2 ratio
values were generated by subtracting median expression
values for WT vehicle-treated animals from each sample
per probe before importing into TIGR MeV 4.0 software
for statistical analysis [52]. The Significant Analysis of
Microarrays (SAM) algorithm was used to correct for
multiple comparisons and non-parametrically select differ-
entially expressed genes using a median false discovery
rate (FDR) ≤1.0 % [53]. In addition, a two-factor analysis
of variance (ANOVA) was performed. To generate a data
sets similar in size and false-positive rates, a P value
<0.005 was employed. The lists of differentially
expressed genes generated via SAM or ANOVAwere then
compared to identify 8110 shared transcripts for further
investigation and validation (Fig. S2). This output was
subjected to appropriate pair-wise SAM comparisons, in-
corporating a 1.5-fold change cut-off [54]. Significant
transcripts were annotated using Ingenuity Pathway
Analysis (IPA) (v8.7; Ingenuity® Systems, Redwood
City, CA, USA), providing insight into biological/
molecular themes over-represented in response to A2AR
deletion and/or LPS. In brief, for each pathway/process,
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the fraction of differentially expressed genes was com-
pared with the fraction of total genes in that path (shown
in tables as the ‘Ratio’, useful for determining which
pathways/processes overlap the most with altered genes
in specific datasets). The probability of involvement of
the respective number of modified transcripts in a
path/process is expressed as a P value or range (values
<0.05 considered significant).
Validation of expression changes and Adora expression via
RT-qPCR
Two-step RT-qPCR, utilizing SYBR Green I, was
employed to confirm differential gene expression for 11
transcripts (primer details provided in Table S1), as pre-
viously described [54]. Six additional genes (Actb,
Gapdh, Hprt1, Pgk1, Ppia and Ubc) were assessed using
GeNorm to determine utility as reference genes [55].
Following GeNorm assessment, Actb was found to be
most stable (M = 0.03) and served as the endogenous
reference control for all messenger RNAs (mRNAs)
assessed via RT-qPCR. Briefly, 1 μg total RNA was used
to synthesize cDNA using the Superscript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA, USA) ac-
cording to manufacturer’s instructions. RT-qPCR was per-
formed in a CFX96 Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). Final reaction volumes
(10 μL) included 5 μL iQ SYBR-Green Supermix (Bio-
Rad, Hercules, CA), 100 nM of each primer and 4 μL of a
1:20 dilution of cDNA. Optimal qPCR cycling conditions
entailed an initial denaturation at 95 °C for 3 min follow-
ed by 40 cycles of 95 °C for 15 s/62 °C for 60 s. After the
final PCR cycle, reactions underwent melt curve analysis
to detect non-specific amplicons. All reactions were per-
formed in triplicate, with each plate containing an equal
number of samples from each group, a calibrator control
derived from a pool of all cDNA samples and a no-
template control. PCR amplification efficiencies (90–
110 %) for each primer pair were calculated using a 5-
log serial dilution of calibrator sample. PCR data were
Fig. 1 Effects of A2AR KO and LPS (24 h) on markers of cardiac
damage (TnI) and systemic inflammation (CRP) and the acute phase
response (haptoglobin). Data represent means ± S.E.M. *P < 0.05 vs.
vehicle; †P < 0.05 vs. wild-type
Table 1 Ex vivo cardiovascular
function in perfused for hearts
from WT and A2AR KO mice





KO + LPS(n = 9)
Coronary flow (ml/min/g) 16.7 ± 0.7 15.6 ± 1.2 16.9 ± 1.7 15.9 ± 0.6
Heart rate (beats/min) 341 ± 7 341 ± 7 352 ± 9 353 ± 9
Systolic pressure (mmHg) 113 ± 6 118 ± 5 80 ± 7* 86 ± 3*
+dP/dt (mmHg/s) 6039 ± 247 6039 ± 163 4310 ± 422* 4489 ± 220*
−dP/dt (mmHg/s) −3664 ± 129 −3718 ± 132 2666 ± 197* −2846 ± 105*
Coronary ‘Supply:Demand’ (ml/
min/g/mmHg)
0.15 ± 0.01 0.13 ± 0.02 0.21 ± 0.02* 0.18 ± 0.02*
All data are means ± S.E.M. Functional parameters were measured after 30 min of normothermic aerobic
perfusion. Intrinsic heart rate is recorded immediately prior to pacing. *P < 0.05 vs. corresponding values in
Vehicle-treated hearts. Coronary ‘Supply:Demand’ was calculated as the ratio of coronary flow rate (O2 supply)
relative to ventricular systolic pressure (reflecting myocardial O2 demand). dP/dt, first derivative of pressure over
time. *P < 0.05 vs. untreated. A2AR KO did not independently modify functional parameters
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analysed using CFX Manager v1.6 (Bio-Rad, Hercules,
CA). Baseline subtractions and threshold settings above
background were applied to all data. The calibrator sam-
ple was used to normalize inter-assay variations, with the
threshold coefficient of variance for intra- and inter-assay
replicates <1 % and <5 %, respectively. Normalized ex-
pression (ΔΔCq) was calculated, with mRNAs normal-
ized to Actb levels and the calibrator control then log2-
transformed.
Results
Impact of A2AAR deletion on cardiovascular function
and inflammatory markers
Deletion of the A2AR was confirmed in cardiac tissue,
with no compensatory changes in transcription of the
other three sub-types (Fig. S1). Receptor deletion did
not modify cardiac or coronary function in healthy or
endotoxemic hearts (Table 1). Cardiovascular, blood cell
and cytokine responses to LPS in WT and A2AR KO
mice have been reported by us previously [23]. Similar
outcomes were apparent here for markers of inflamma-
tion and injury (Fig. 1), haematological parameters and
cytokines (Fig. 2) and cardiac function (Table 1). Data
confirm significant inflammatory activation, cellular in-
jury and cardiac dysfunction with LPS, with A2AR de-
letion amplifying changes in IL-5 and markers of cardi-
ac injury (TnI) and systemic inflammatory stress (hap-
toglobin, CRP), without altering myocardial dysfunction
or circulating levels of IL-4, IL-10, IFNγ or TNFα.
Impact of A2AAR deletion on survival
Interestingly, we acquire preliminary evidence LPS-
dependent mortality is age- and sex-dependent and selectively
exaggerated by A2AR KO in older males (Fig. S3). Initially,
Fig. 2 Effects of A2ARKO and LPS (24 h) on haematological parameters and cytokines. Data representmeans ± S.E.M. *P < 0.05 vs. vehicle; †P < 0.05
vs. wild-type
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testing responses to LPS challenge in young (14 week) and
middle-aged (46–52 week) mice—since age may exaggerate
impacts of endotoxemia [56]—we recorded 20 % mortality in
older WT mice with A2AR KO specifically reducing survival
to <20 % in older males (Fig. S3). No mortality was recorded
in young mice challenged with LPS (or any vehicle-treated
groups). There is thus a trend to greater mortality with age,
with a major survival effect of A2AR activity in older males.
While molecular interrogations here are thus limited to young
mice (in which LPS was non-lethal), it is possible A2AR ac-
tivity may be increasingly crucial to survival in older, stress-
intolerant males (whereas younger animals and females may
possess intrinsically greater resistance to injury/death [57]).
This is discussed further in the online Supplementary material.
Cardiac transcriptomic response to A2AR KO
Few transcriptional differences were detected between WT
and A2AR KO hearts, with the amplitude of changes modest
(up to threefold). Employing an initial 1.5-fold cut-off and 1%
FDR identified only 13 genes (Table 2). To enhance the power
of subsequent pathway analysis, these criteria were relaxed to
1.2-fold and 5 %, encompassing 37 altered transcripts
(Table 2). There was a little impact of A2AR deletion on in-
flammatory mediators, with modest induction of a CXC che-
mokine (Ppbp, +2.1), a regulator of cell migration/adhesion
and cytokinesis (Iqgap1, +1.6) and a hemopoietic cytokine
(Tslp, +1.6), together with repression of Hp (−2.7) and an Ig
adhesion molecule regulating T-lymphocyte development
(Mpzl2, −1.7) (Table 2).
Analysis via the IPA suite identified 112 canonical path-
ways sensitive to A2AR activity in healthy hearts (Table S2),
the most highly modified shown in Table 3. The top five
included relaxin signalling, cardiac β-adrenergic signalling,
cellular effects of sildenafil, PKA signalling and photo-trans-
duction. The influence of A2AR KO on these and other paths
can be attributed to repression of Prkar2b (−1.8),Gnb1 (−1.7)
and Pde3b (−1.7), collectively impacting G protein-coupled
cAMP/PKA dependent signalling (encompassing relaxin, α-
and β-adrenergic, NO, Ca2+ and hypertrophic signalling).
Additionally,Map3k2 (−2) andNfat2c (+1.3) spanmany paths
modified by A2AR KO. Modulation of these five transcripts
contributes to 48 of the top 50 A2AR-sensitive canonical path-
ways. Overall, A2AR deletion exerts an inhibitory effect on G
protein-coupled, cAMP/PKA, and MEKK2 signalling down-
stream of this and other GPCRs.
Multiple biological functions appear sensitive to A2AR KO
(see Table S3), the most significant (Table 4) revolving around
cellular development, growth, movement and death, together
with humoral immunity and haematological development and
intercellular signalling. Toxicological functions included high
representation of liver processes (fibrosis, damage, steatosis,
hepatitis and inflammation) together with six cardiac
functions (Table 4). The latter included cardiac arteriopathy
(Ank3, Pon1, Cux2, Gk5, Pde3b, Dgat1 and Nsmce1), infarc-
tion (Pon1 and Acta1) and transcripts involved in failure and
hypertrophy (Pde3b and Nfat2c).
Cardiac transcriptomic response to LPS
Analysis via the SAM algorithm (1.5-fold threshold, 1 %
FDR) identified 4146 transcripts modified after 24 h of LPS
challenge (see Table S4 for full details). Figure 3 presents the
25 most induced and repressed transcripts, with responses in
A2AR KO hearts shown for comparison. Many of the most
highly modified are predictably involved in inflammation/
innate immunity, together with tissue development/remodel-
ling. The most LPS-responsive cytokines/chemokines are
shown in Fig. 4, with responses in KO hearts highlighted.
Functional classifications, using a twofold threshold to nar-
row the focus to the most highly modified paths, identify 236
canonical pathways (Table S5), with the most significantly
modified presented in Table 5. Data confirm a profound in-
flammatory and immune response, with marked upregulation
of TLR/MyD88 and interferon signalling (Fig. 5), the acute
phase response (Fig. S4), IRF activation (Fig. S5) and PRR-
and RIG-1-like signalling (Figs. S6 and S7). These changes
primarily reflect shifts in underpinning NFκB, JAK-STAT,
MAPK and PI3K/Akt signall ing (Figs. S8–S12).
Additionally, LPS upregulated cell death signalling
(Figs. S13 and S14) and modified paths involved in cellular
differentiation, movement, growth and remodelling (e.g.
Figs. S15 and S17). The top LPS-sensitive biological func-
tions are summarized in Table S6, with biologic and cardio-
vascular toxicological responses fully detailed in Table S7 and
S8 in the Supplementary material.
Unsurprisingly, many highly responsive transcripts were
involved in inflammation (Figs. 3 and 4, Table 5): within the
most induced are interferon-related genes (Ifit1, Ifit2, Ifit3,
Igtp1, Igtp2, Igtp3, Iigp1, Iigp2, Ifi44 and Irf7) and
inflammatory/immune modulators (Lcn2, Saa3, Socs3,
S100a8, S100a9, Mpa2l, Cxcl1, Cxcl9, Cxcl10, IL6, Ptx3,
Serpina3n, Csf3 and Mt2). Several are potentially injurious
to the heart: the most highly induced transcript encodes
lipocalin-2, which regulates inflammation and matrix degra-
dation, is implicated in heart failure [58] and promotes cardiac
apoptosis [59]; CXCL1 is a potent neutrophil chemoattractant;
CXCL9 stimulates cytokine production and T-cell
proliferation/recruitment; CXCL10 mediates CXCR3+ cell
migration and augments inflammation. Conversely, some
transcripts encode anti-inflammatory and potentially protec-
tive molecules: SERPINA3N (α1-antichymotrypsin) inhibits
proteases involved in inflammation; the pentraxin PTX3 is
expressed in heart with inflammation and limits cell death;
SOCS3 is a negative feedback regulator of IL-6 signalling,
implicated in sex-dependent cardiac stress-resistance;
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metallothionein-2, induced by STAT3-related signalling, me-
diates cardioprotection and can limit dysfunction in sepsis.
Cardio-depressant molecular profileMajor pathways crit-
ical to contractile function were substantially impacted,
identifying a ‘cardio-depressed’ molecular profile in
hearts of endotoxemic mice (Figs. S18–S21). β-
Adrenerg ic s igna l l ing was broad ly suppressed
(Fig. S18), including reduced transcripts for β1-adrenergic
receptor, G protein, adenylate cyclase, PKA and related
signalling elements (Ppp1r14c, Gng11, Prkar2b, Pde7a,
Ppp1r3c, Ppp1r14a, Pkia and Adcy7), together with in-
duction of Pde4b (AMP-dependent phosphodiesterase).
The PKA pathway itself was substantially suppressed
Table 2 Genes modified by A2AR KO in healthy myocardium
Gene Gene name Affymetrix ID Fold-Change %FDR
UpRegulated
Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase 1439811_at 2.83 0.00
Ppbp pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) 1418480_at 2.08 3.93
Chac1 ChaC, cation transport regulator homologue 1 (E. coli) 1451382_at 1.85 0.00
Ctsk cathepsin K 1450652_at 1.84 0.00
Cnpy2 canopy 2 homologue (zebrafish) 1416507_at 1.67 0.00
Iqgap1 IQ motif containing GTPase activating protein 1 1445724_at 1.64 3.85
Tslp thymic stromal lymphopoietin 1450004_at 1.63 3.93
Nav3 neuron navigator 3 1456144_at 1.61 0.00
Cux2 cut-like homeobox 2 1447500_at 1.60 0.00
Slc38a1 solute carrier family 38, member 1 1454764_s_at 1.47 0.00
Nsmce1 non-SMC element 1 homologue (S. cerevisiae) 1436121_a_at 1.42 0.00
Gk5 glycerol kinase 5 (putative) 1436210_at 1.38 3.93
Rpl22 ribosomal protein L22 1448398_s_at 1.37 0.00
C11orf75 chromosome 11 open reading frame 75 1419403_at 1.37 0.00
Slco5a1 solute carrier organic anion transporter family, member 5 A1 1440874_at 1.31 4.21
Nfatc2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 1426032_at 1.28 4.70
Downregulated
Dgat1 diacylglycerol O-acyltransferase homologue 1 (mouse) 1418295_s_at −1.24 2.39
Ticam1 toll-like receptor adaptor molecule 1 1454676_s_at −1.24 3.05
Mrap melanocortin 2 receptor accessory protein 1451371_at −1.31 3.05
Ppa1 pyrophosphatase (inorganic) 1 1416939_at −1.32 4.31
Ell2 elongation factor, RNA polymerase II, 2 1450744_at −1.33 2.53
Fmod fibromodulin 1456084_x_at −1.47 4.31
Ptger3 prostaglandin E receptor 3 (subtype EP3) 1450344_a_at −1.49 2.68
Pkdcc protein kinase domain containing, cytoplasmic homologue (mouse) 1454838_s_at −1.50 4.61
Ank3 ankyrin 3, node of Ranvier (ankyrin G) 1457288_at −1.58 3.05
Sacs spastic ataxia of Charlevoix-Saguenay (sacsin) 1434958_at −1.61 2.39
Pon1 paraoxonase 1 1418190_at −1.68 0.00
Gnb1 guanine nucleotide binding protein (G protein), beta polypeptide 1 1425908_at −1.72 4.54
Mpzl2 myelin protein zero-like 2 1416236_a_at −1.74 0.00
Pde3b phosphodiesterase 3B, cGMP-inhibited 1433694_at −1.74 0.00
Prkar2b protein kinase, cAMP-dependent, regulatory, type II, beta 1438664_at −1.78 3.05
Slc16a9 solute carrier family 16, member 9 (monocarboxylic acid transporter 9) 1429726_at −1.84 0.00
Map3k2 mitogen-activated protein kinase kinase kinase 2 (MEKK2) 1438719_at −2.01 0.00
Cidec cell death-inducing DFFA-like effector c 1452260_at −2.08 0.00
Acta1 actin, alpha 1, skeletal muscle 1427735_a_at −2.14 2.68
Yipf4 Yip1 domain family, member 4 1426417_at −2.51 4.54
Hp haptoglobin 1448881_at −2.70 0.00
Data shown for transcripts for which myocardial expression levels were modified by A2AR KO by a factor of ≥1.2-fold (FDR <5 %)
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(Fig. S19), including reductions in PKA RIα (Prkar1a),
PKA RIIα (Prkar2a), PKA RIIβ (Prkar2b), PKAα
(Prkaca) and PKA-Cβ (Prkacb), while PKA RIβ
(Prkar1b) was modestly induced (+1.5). Transcripts for
Gαs and Gαq also declined.
Cellular Ca2+ signalling paths were repressed (Fig. S20),
with reductions in key elements including: Camk1d, Ryr3,
Casq1, Mef2c, Casq2, Calm1, Hdac9, Myh7b, Tpm2,
Myh11, Rcan1, Myl7, Atp2b2, Prkar2b, Tpm3 and Asph.
Mitochondrial dysfunction (Fig. S21) is also evidenced by
repression of complex I/NADH dehydrogenase components
(includingNdufv2 and 3; Ndufs4, 5, 6, 7 and 8; Ndufa3, 4, 5, 6
and 8; Ndufab1, Ndufaf1, Ndufb2, 3, 4, 7, 9, 10 and 11),
together with Complex II components (including Sdhc,
Sdhd, Uqcrb, Uqcrc1 and Uqcrfs1). Uncoupling proteins
Ucp2 andUcp3were also induced, whileUcp1was repressed.
Transcript for the major activator of mitochondrial biogenesis
(Ppargc1a) was repressed.
Adenosine-related transcripts There were limited impacts on
the adenosinergic system itself, with two- to threefold upregu-
lation of adenosine deaminase, 1.5-fold repression of adenosine
kinase, 1.7-fold induction of S-adenosylhomocysteine hydro-
lase and twofold induction of the ecto-nucleotidase CD39.
These changes may modify patterns of cellular adenosine gen-
eration vs. uptake and metabolism, potentially altering receptor
activation in endotoxemic tissue. A small 1.3-fold rise in
Adora2b expression was also detected.
Impact of A2AR KO on transcriptomic responses
to endotoxemia
Interestingly, A2AR activity does not broadly suppress the
effects of endotoxemia on myocardial gene expression, with
90 % of transcriptomic responses unaltered by receptor KO.
For example, Fig. 3 presents response profiles for the 25 most
induced or repressed transcripts in WT hearts, with most
shown to be insensitive to A2AR KO. Deletion selectively
enhanced induction of Lcn2, Igtp, Cxcl5, S100a8, Iigp2,
Cxcl2 and Iigp1 and repression of C1qtnf9, Colec11 and
Inmt, while reducing induction of Ifit3 and repression of
Adipoq, Gpr22, and Scube2, Ifit3 (Fig. 3). These effects sup-
port A2AR modulation of inflammatory and interferon-related
signalling responses. Nonetheless, the pattern of LPS-
dependent cytokine/chemokine changewas largely insensitive
to A2AR KO, with specific enhancement of Cxcl5, Cxcl2, Il6
and Csf3 induction (Fig. 4). Figure 6 summarizes the select
effects of A2AR activity (revealed via KO) on TLR- and
interferon-triggered NFκB and JAK-STAT signalling re-
sponses to LPS (generally repressing these pathways).
To gain further insight into these specific effects of A2AR
KO, we identified those LPS-responsive transcripts whose
expression changes were increased or reduced ≥1.5-fold by
A2AR KO (Table S9). Effects of LPS on 282 genes were
augmented ≥1.5-fold following A2AR KO, with a further 9
responsive to LPS specifically in KO and not WT hearts
(Table S9). The most highly augmented included 25 tran-
scripts increased ≥twofold by KO. Many A2AR-sensitive tran-
scripts are associated with pro-inflammatory signalling (e.g.
Igtp, Lcn2, Cxcl5, S100a8, Iigp2, Cxcl2, Il6, Ifi202b, Hp and
Cxcl9), with data supporting inhibitory effects of the A2AR on
the responsiveness of canonical pathways that include the
acute phase response, glucocorticoid receptor, Erk/MAPK,
HIF1α and JAK-STAT signalling (Table 6).
Deletion of the A2AR reduced or entirely eliminated 134
gene responses to LPS (Table S9). Responses entirely A2AR-
dependent included repression of Sacs, Cidec, Gnb1l,
Mtap1b, Msi2, Cdh2, Lpgat1, Tbx3, Slc38a1, Sdc1, Reln,
Ext1 and Pvrl3, and induction of Rit1, Ezh1, Eif4ebp1 and
Abhd4 (Table S9). The transcripts most sensitive to A2AR
KO included Dnmt3a, Qk, Sema5a, Srpk2, Car3, Ucp1,
Rsad2 and Dnajb14. Highly LPS-responsive changes
counteracted by A2AR KO included: Ifit3, Rsad2, Cxcl13,
Ms4a6d, Oasl1, Ms4a4c, Sema5a, Tyki and Hmox1. Intrinsic
A2AR activity thus also promotes LPS-dependent shifts in
select genes associated with immune/inflammatory processes,
including orphan nuclear receptor and PPARα activation,
PRR responses to infection, AMPK signalling and NFκB sig-
nalling (Table 6).
In terms of biological functions, A2AR activity reduced
LPS responsiveness of paths related to cellular movement,
growth, signalling and death, immune cell trafficking and
haematological and cardiovascular development (Tables 7
and S10). Conversely, A2AR activity appears to augment
responses in pathways related to metabolism and trans-
port, together with organ, haematological, cardiovascular
and lymphoid development (Table 7), with complete de-
tails of pathway responses modified by A2AR KO includ-
ed in Table S10. Deletion of the A2AR also influenced
multiple toxicological functions; of 35 responses coun-
tered by A2AR KO, 12 were cardiac-specific categories
(Table S11), with reduced Adipoq and Hmox1 responses
involved in ~half. Of 46 toxicological function responses
enhanced by A2AR KO, a third was cardiac categories.
Enhanced responses for Serpine1, Kckn3 and Ppargc1a
are involved in a majority of these and are also implicated
in cardiac dysfunction.
Importantly, a relatively small set of A2AR responsive
genes are implicated in a majority of these A2AR sensitive
biological pathways and processes and can be considered
A2AR-dependent ‘nodes’ or points of regulatory conver-
gence. Of the top 50 pathway responses augmented by
A2AR KO, Pi3kr1 is implicated in 42; Rras2 in 40;
Stat1, Vegfc, Pgf and Pak6 each in 12; Atf4 in 11;
Cdkn1a in 9 and Rhoj and IL6 each in 8 (Tables 6 and
S10). Of the leading 50 canonical responses inhibited by
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A2AR KO, Rac2 was implicated in 34, Nfkbie in 21,
Prkar2b in 10, Hmox1 and Eif2ak2 each in 6 and
Eif4ebp1 and Cyp2b6 each in 5 (Tables 6 and S10).
These data point to an influence of intrinsic A2AR activity
on key signalling responses, including G protein, PKA,
STAT1 and NFκB -d e p e n d e n t p r o c e s s e s ( s e e
Supplementary material for additional discussion). While
the absence of A2ARs impacted inflammatory and under-
lying signalling changes in endotoxemia, paths implicated
in endotoxemic cardio-depression (ß-adrenergic and PKA
signalling, Ca2+ handling, excitation-contraction coupling
and mitochondrial function; Figs. S18–S21) were not
among those sensitive to A2AR KO (Table 6), consistent
with a lack of effect of A2AR KO on contractile dysfunc-
tion itself (Table 1).
PCR analysis of select transcripts
Quantitative RT-PCR analysis supports microarray-
determined changes in transcripts selected for differen-
tial responsiveness to LPS and A2AR KO (Fig. 7).
While expression ratios vary slightly between the two
methods, a significant linear relationship was apparent
between both measures (with a slope > 1 suggesting
greater dynamic range for RT-qPCR measurement).
Discussion
The present study characterizes impacts of A2AR dele-
tion on the myocardial transcriptome, markers of inflam-
mation and cardiac function and injury in healthy and
endotoxemic mice. Data indicate A2AR activity exerts
limited effects in un-stressed myocardium, with
t r ansc r ip tomic changes l imi ted to G pro te in ,
cAMP/PKA and cGMP/NO signalling downstream of
this and other GPCRs (Tables 2 and 3). However, dur-
ing endotoxemia, absence of A2ARs exaggerated myo-
cardial injury (and age- and sex-dependent mortality),
without substantially modifying patterns of cytokine re-
lease, myocardial cytokine/chemokine transcription or
contractile depression. The latter is consistent with in-
sensitivity of the ‘cardio-depressant’ profile in
endotoxemic hearts to A2AR KO. Rather, data reveal
A2AR activity selectively influences transcription of reg-
ulators of NFκB and JAK-STAT signalling during
endotoxemia, which may limit myocardial inflammation
Table 3 Top 20 canonical pathways modified by A2AAR KO in healthy myocardium
Canonical pathways P value Ratio Genes
Relaxin signalling 3.55E-03 1.99E-02 Gnb1, Prkar2b, Pde3b
Cardiac β-adrenergic signalling 3.55E-03 2.11E-02 Gnb1, Prkar2b, Pde3b
Cellular effects of sildenafil (Viagra) 3.98E-03 1.99E-02 Acta1, Prkar2b, Pde3b
Protein Kinase A signalling 6.03E-03 1.26E-02 Gnb1, Prkar2b, Pde3b, Nfatc2
Phototransduction pathway 6.03E-03 3.08E-02 Gnb1, Prkar2b
Germ cell-sertoli cell junction signalling 6.31E-03 1.88E-02 Iqgap1, Acta1, Map3k2
Calcium signalling 8.71E-03 1.47E-02 Prkar2b, Nfatc2, Acta1
Glutamate receptor signalling 9.55E-03 2.86E-02 Gnb1, Slc38a1
Caveolar-mediated endocytosis signalling 1.41E-02 2.35E-02 Acta1, Map3K2
Nitric oxide signalling in the cardiovascular system 1.48E-02 2.02E-02 Prkar2b, Pde3b
Leptin signalling in obesity 1.55E-02 2.38E-02 Prkar2b, Pde3b
Cardiac hypertrophy signalling 1.78E-02 1.22E-02 Gnb1, Prkar2b, Map3k2
TR/RXR Activation 2.09E-02 2.02E-02 Hp, Pde3b
SAPK/JNK signalling 2.14E-02 1.98E-02 Gnb1, Map3k2
Colorectal cancer metastasis signalling 2.14E-02 1.17E-02 Gnb1, Prkar2b, Ptger3
α-Adrenergic signalling 2.19E-02 1.89E-02 Gnb1, Prkar2b
RANK signalling in osteoclasts 2.19E-02 2.04E-02 Nfatc2, Map3K2
G Beta Gamma signalling 2.24E-02 1.68E-02 Gnb1, Prkar2b
IL-1 signalling 2.29E-02 1.89E-02 Gnb1, Prkar2b
fMLP signalling in neutrophils 2.95E-02 1.57E-02 Gnb1, Nfatc2
Canonical signalling paths modified by A2AR KO are shown, ranked according to P values determined by a Fisher’s Exact Test. Also shown is a ratio
value reflecting the number of molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in
the pathway
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and injury. Additional changes with A2AR KO suggest
potential influences on insulin-resistance, hypertrophy/
remodelling and vascular control/angiogenesis in
endotoxemia.
A2AR activity and the transcriptome in un-stressed
myocardium
Modest impacts of A2AR KO in un-stressed hearts
(Table 2) are consistent with a largely retaliatory or
stress-responsive role for myocardial A2ARs. Indeed, de-
letion failed to modify cardiac or vascular function, and
circulating CRP, haptoglobin and cytokines in healthy an-
imals. Functional annotation of transcripts supports A2AR-
dependent shifts in relaxin, adrenergic, Ca2+, PKA,
SAPK/JNK and hypertrophic pathways (Tables 3 and
S2), involved in cellular growth/movement/death, immune
and cell-to-cell signalling, and toxicological processes of
fibrosis, cell damage and inflammation. This profile stems
from a handful of changes spanning pathways (i.e. Gnb1,
Nfat2c, Acta1, Prkar2b, Map3k2 and Pde3b), supporting
effects of A2AR activity on G protein and cAMP/PKA
signalling downstream of the receptor [5, 8, 60].
Deletion of the A2AR has been shown to reduce cAMP
and PKA activation in other cell types [61], consistent
with impacts of KO here (Table 3). The altered MEKK2
path is also linked to G protein/Rac-dependent signalling
distal to this and other GPCRs. In terms of vasoregulatory
functions of the A2AR, shifts in inter-related pathways
involved in relaxin signalling, cellular effects of sildenafil
and NO signalling (Table 3) support modulation of
cGMP/NOS dependent control, while cardiac arteriopathy
was identified as a pathologic process sensitive to A2AR
KO (Table 4). These rather limited transcriptomic changes
in healthy myocardium are consistent with observations in
other tissues. For example, Yu et al. [62] found A2AR KO
alters a very small sub-set of transcripts in healthy stria-
tum (implicating A2AR sensitive EGR-2 control), with
expression changes also modest (a majority ≤twofold).
Others report no impact of A2AR KO on myocardial ex-
pression of RAC1, ERK1/2, p38-MAPK or JNK [14],
though phospho-activation of the latter kinases was im-
paired, potentially reflecting shifts in cAMP/PKA and
MEKK2 signalling.
Transcriptomic profile of endotoxemic myocardium
Myocardial injury and dysfunction are critical determi-
nants of circulatory changes and mortality with uncon-
trolled inflammation; however, their mechanistic basis is
poorly defined. Transcriptomic interrogation can reveal
elements of these complex responses, though there are
f ew ana ly se s o f myoca rd i a l [ 41 , 42 , 49 ] o r
cardiomyocyte [43, 49] responses to endotoxin/sepsis.
Approximately 15 % of the 25,646 transcripts expressed
in murine hearts were modified in endotoxemia
(Table S4), encompassing a multiplicity of canonical
paths and functions (Tables 5, S5–S7). Many are con-
sistent with those highlighted by Wong et al. in more
limited analysis of endotoxemic rats [41] and Rudiger
et al. in a rat faecal peritonitis model [49]. The myo-
cardial response involves profound upregulation of
immune/inflammatory paths (Figs. 3–5 and S4–S7), the
most highly modified including acute-phase response,
PRR/TLR and interferon/IRF signalling (Table 5).
Underlying NFκB, JAK-STAT and MAPK/PI3K paths
are up-regulated (Tables 5, S5 and S7; Figs. S8–S12),
with NFκB/JAK-STAT mechanistically linking the top
five canonical pathway responses. Integrated signalling
via NFκB and JAK-STAT paths thus appears central to
myocardial endotoxemia, as in other tissues. In other
tissues, these paths are also targeted by A2ARs to sup-
press inflammatory/immune responses [44, 45, 58], with
KO augmenting NFκB activation in macrophages, for
example [6].
Amplified cardiac TLR and interferon signalling Since
uncontrolled inflammation induces cellular injury/death,
pro-inflammatory TLR/CD14 signalling is the subject to
negative control. However, this path was transcriptional-
ly amplified in endotoxemic myocardium (Fig. 5), in-
cluding receptor molecules (Cd14, Tlr1, Tlr2, Tlr3 and
Tlr4) and LPS-binding protein (Lbp), transduction mol-
ecules (Cr3/Mac1 and Cr4), MyD88, TIRAP and
MyD88 targets (Il6 and Il1b), MyD88-independent sig-
nal components (Tbk1, Cxcl10, Ccl2 and Ccl5) and
downs t r e am JAK-STAT s igna l l i ng (F ig . S9 ) .
Upregulated TLR and MyD88-dependent and indepen-
dent signalling are consistent with changes in rat sepsis
[49], though Tlr4, Cd14 and Tirap induction here was
not apparent in the rat model. Sweeney et al. [63] re-
cently reported a novel MyD88-independent path linking
TLR2/TLR4 signalling to Ppargc1a, encoding the mito-
chondrial biogenesis co-regulator PGC-1α. However,
despite induction of elements of this path here (includ-
ing Tlr2, Tlr3, Tlr4 and Irf7), cardiac Ppargc1a was
repressed by LPS, a response potentially exaggerating
mitochondrial dysfunction and countered by A2AR
activity.
Interferon signalling transducing inflammatory/TLR
responses was also upregulated (Fig. 5), including a
majority of gene targets and the path of IRF activation
by PRRs (Figs. S5–S7). This entailed induction of
membrane (Tlr2, Tlr3 and Tlr4), cytosolic (Ddx58,
Ifih1, Eif2ak2 and Oas1) and extracellular (C1q, C3,
C3a and Ptx3) receptors, and downstream mediators
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(Il6, Irf7 and Rantes). These shifts in TLR/CD14,
MyD88-dependent and -independent and interferon/IRF
signalling are relevant to temporal expansion of molec-
ular changes [41, 42] and injury progression in
Table 4 Top 20 biological and toxicological functions modified by A2AAR KO in healthy myocardium
Biological pathway P values Genes
Cellular development 7.34E-04–4.5E-
02
Mrap, Ctsk, Sacs, Prkar2b, Ptger3, Nfatc2, Tslp, Map3k2
Cellular growth and proliferation 7.34E-04–4.01E-
02
Mrap, Ppbp, Nfatc2, Tslp




Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Tslp, Map3k2
Humoral immune response 7.34E-04–4.5E-
02
Nfatc2, Fmod, Tslp
Cell-to-cell signalling and interaction 1.53E-03–4.74E-
02
Ank3, Ptger3, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp, Map3k2





Gnb1, Pon1, Ppbp, Ppa1
Cell death 2.55E-03–4.5E-
02
Ppbp, Nfatc2, Tslp, Map3k2
Cell morphology 2.55E-03–3.68E-
02
Ank3, Ptger3, Nfatc2, Cnpy2, Iqgap1, Tslp
Cellular assembly and organization 2.55E-03–4.01E-
02
Ank3, Ctsk, Nfatc2, Fmod, Cnpy2, Iqgap1, Acta1
Cellular compromise 2.55E-03–4.01E-
02
Ank3, Hp, Ctsk, Ptger3, Ppbp
Cellular function and maintenance 2.55E-03–1.52E-
02
Hp, Ppbp, Nfatc2, Tslp, Map3k2
Cellular movement 2.55E-03–4.58E-
02
Gnb1, Ctsk, Hp, Ticam1, Ppbp, Nfatc2, Iqgap1, Tslp
Connective tissue development and function 2.55E-03–3.02E-
02
Ctsk, Rpl22, Ptger3, Pde3b, Ppbp, Cidec, Nfatc2








Ank3, Ctsk, Ptger3, Cidec, Iqgap1, Tslp, Mrap, Gnb1, Pon1, Hp, Prkar2b, Pde3b, Nfatc2,
Dgat1, Acta1
Hair and skin development and function 2.55E-03–5.09E-
03
Ptger3, Dgat1
Immune cell trafficking 2.55E-03–3.51E-
02
Hp, Ticam1, Ppbp, Nfatc2, Tslp
Inflammatory response 2.55E-03–4.67E-
02
Hp, Ptger3, Ticam1, Ppbp, Nfatc2, Fmod, Tslp
Molecular toxicological function P values Genes
Liver fibrosis 3.01E-03 Hp, Tslp
Liver damage 1.43E-02 Ticam1, Tslp
Liver steatosis 2.45E-02 Pde3b
Cardiac arteriopathy 3.41E-02 Ank3, Cux2, Dgat1, Gk5, Nsmce1, Pde3b, Pon1
Cardiac infarction 3.76E-02 Acta1, Pon1
Liver hepatitis 4.41E-02 Pde3b
Hepatocellular carcinoma 4.43E-02 Hp, Iqgap1
Liver steatohepatitis 5.67E-02 Pde3b
Renal proliferation 7.90E-02 Tslp
Liver inflammation 9.36E-02 Hp
Pulmonary hypertension 1.08E-01 Ptger3
Nephrosis 1.10E-01 Pde3b
Cardiac congestive cardiac failure 1.63E-01 Pde3b
Heart failure 1.63E-01 Pde3b
Renal nephritis 2.50E-01 Pde3b
Enriched biological/toxicological functions of A2AR KO sensitive transcripts are listed according to P values or ranges determined by a Fisher’s Exact
Test
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endotoxemia: CD14 [64] and TLR4 [65, 66] both me-
diate cardiac dysfunction and injury and MyD88 signal-
ling promotes cardiac hypertrophy [67], inflammation
and injury [68, 69]. These profound responses diverge
from in vitro data suggesting dampened/transient im-
pacts of LPS on isolated myocyte NFκB and IκB kinase
[43, 63].
Endotoxemic cardio-depression Cardiomyocyte and myo-
cardial function is LPS-sensitive and depressed in
endotoxemia [21, 23, 70, 71] (Table 1). This has been linked
to abnormalities in myofibrillar Ca2+ sensitivity [70, 71], ad-
renergic control [71–74] and mitochondrial function [75], to-
gether with cell death [23, 76, 77]. Transient changes in pre-
loadmay alsomediate early reversible depression in vivo [78].
Transcriptomic data reveal a cardio-depressant profile
entailing suppression of key determinants of contraction, in-
cluding Ca2+, β-adrenergic and PKA signalling, mitochondri-
al function and electromechanical coupling (Figs. S18–S21).
Importantly, and despite other impacts, A2AR expression did
not influence this cardio-depressant profile nor modify con-
tractile depression (Table 1) [23].
Suppression of β-adrenergic and Ca2+ signalling is
consistent with desensitization in hearts and myocytes
[71–73], and transcriptional changes in a rat model of
faecal peritonitis [49]. Despite overlap with the latter
response, the β1- rather than β2-adrenoceptor is de-
pressed in endotoxemic mouse heart (Fig. S18), while
reductions in AKAP, PP1, PP2A, NCX and L-type Ca2+
channel components observed here were not evident in
the peritonitis model. Nonetheless, data collectively im-
plicate β-adrenergic dysfunction as a common
component of cardio-depression, consistent with reduc-
tions observed in β-adrenoceptor expression [73], tissue
noradrenaline and adrenaline [73] and adrenoceptor
stimulation of cAMP and Ca2+ fluxes [73]. In terms of
approaches to inotropic support, coincident depression
of adrenoceptor, PKA and Ca2+ signalling may limit
the value of interventions targeting these effectors.
Abnormalities within the contractile apparatus itself (re-
pressed α-tropomyosin, troponin-T, α-actin and titin
transcription) may also be relevant. Targeting mitochon-
drial dysfunction may more broadly improve cardiac
outcomes: repression of Complex I components
(Fig. S21) is consistent with Complex I specific dys-
function and ROS generation in mitochondria from
endotoxemic hearts [75, 79].
Additional cardio-depressant changes include altered
TLR4 and fibroblast factor signalling, suppression of
substrate metabolism and IGF-1 signalling (Fig. S22)
and induction of inhibitory S100a8/S100a9, Icam1,
Vcam1, Cybb (NOX2), Ptgs2 (COX2) and the TNF-α
receptors Tnfr1 and Fas. Marked induction of S100 A8
and S100 A9 (TLR4 activators promoting endotoxemic
injury) has been observed in LPS-treated myocytes, in-
volving MyD88 and NFκB signalling [80]. Intriguingly,
two adipokines with opposing actions, relevant to cardi-
ac dysfunction, were among the most responsive to
LPS. Pro-inflammatory and injurious lipocalin-2 (Lcn2)
was the most induced (~600-fold), consistent with
changes in rodent and human myocarditis [59], while
anti-inflammatory and cardioprotective adiponectin
(Adipoq) was the second most repressed. Lipocalin-2 is
induced via IκBζ (+13 with LPS) and with heart failure,
ischemia and inflammation [81, 82]. Profound induction
Fig. 3 The 25 most induced and 25 most repressed transcripts in hearts
from young (2–3 month) mice challenged with LPS for 24 h. Mice were
injected with 20 mg/kg LPS or saline vehicle and left ventricular tissue
isolated for analysis 24 h later. Data from both wild-type and A2AR KO
hearts are shown for comparison (n = 6–8/group). Data are means ±
S.E.M
Fig. 4 Effects of A2AR KO on the most LPS-responsive cytokines in
wild-type hearts.Micewere injected with 20mg/kg LPS or saline vehicle,
and left ventricular tissue isolated for analysis 24 h later. Data from both
wild-type and A2AR KO hearts are shown for comparison (n = 6–8/
group). Data are means ± S.E.M
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may promote dysfunction given its inflammatory [83],
pro-death [82, 84] and mitochondrial actions [84].
Current data suggest the A2AR may beneficially limit
LPS-dependent IκBζ induction to suppress injurious
lipocalin-2. Highly repressed adiponectin exerts anti-in-
flammatory, anti-oxidant and cardioprotective effects
[85, 86], thus downregulation is also likely to promote
inflammation and sensitize myocardium to oxidative-
stress and cell death. Curiously, Adipoq repression was
reduced with A2AR KO, suggesting a positive influence
of A2AR activity on this response. These and other
changes relevant to pathogenesis of cardiac depression








Socs3, Rac2, Hamp, Serping1, Nfkbie, Socs2, Cp, Saa2, Serpina3, Jak2, Il6, Rbp1,
Nr3C1, C1r, Hmox1, Shc1, Nfkbia, Cfb, Lbp, Serpine1, Nfkbib, Saa1, C3, Tnfrsf1a,





Ifit3, Oas1, Ptpn2, Mx1, Ifi35, Irf9, Psmb8, Jak2, Tap1, Irf1, Ifitm1, Stat2, Stat1






Dhx58, Nfkbie, Zbp1, Irf9, Tbk1, Il6, Nfkb2, Adar, Isg15, Ifih1, Irf7, Nfkbia, Ddx58,
Stat2, Nfkbib, Stat1, Ifit2






Icam1, Lepr, Myh7b (Includes Eg:668,940), Myh11, Ccl5, Il6, Fas, Pgf, Vegfa, Il1r2,
Cxcl3, Igf1, Cyp2e1, Timp1, Lbp, Stat1, Timp2, Egfr, Il4r, Vcam1, Tnfrsf1a, Vegfc,
Igfbp5, Nfkb2, Myl7, Csf1, Cd14




B2m, Rac2, Icam1, Lepr, Nfkbie, Pik3r5, Cd83, Il6, Jak2, Fcgr2b, Fcgr1a, Nfkbia, Hla-
b, Tlr3, Stat1, Nfkbib, Fcgr3a, Hla-c, Myd88, Tnfrsf1a, Relb, Rac1, Nfkb2, Tlr2,
Il1rn, Fcer1g, Stat2, Irf8
Role of macrophages, fibroblasts and





Socs3, Rac2, Icam1, Mmp3, Nfkbie, Pik3r5, Jak2, Ccl5, Il6, Il17ra, Fcgr1a, Pgf, Myc,
C1r, Il1r2, Vegfa, Nfkbia, Traf3Ip2, Wif1, Cfb, Plcb1, Tlr3, Nfkbib, Prkd1, Fcgr3a,
Calm1, Adamts4, Sele, Vcam1, Myd88, Tnfrsf1a, C1s, Daam1, Rac1, Vegfc, Stat3,
Cebpb, Irak3, Tlr2, Hp, Rras2, Il1Rn, Csf1, Cxcl12, Cebpd, Sost, Wnt5a, Irak2




Parp10, Art1, Tnfsf10, Parp3, Parp12, Parp9, Tiparp, Irf1, Parp4, Bid, Parp11, Cflar,
Parp14




B2m, Psmb9, Hla-e, Hla-b, Psmb8, Hla-g, Tap1, Tap2, Tapbp, Hla-c
Role of pattern recognition receptors in





Ptx3, Oas1, C3, Oas2, Myd88, Pik3R5, Il6, Nfkb2, Ccl5, Tlr2, Ifih1, Clec7a, Irf7, Syk,
Ddx58, Eif2ak2, Tlr3










Ccr1, Socs3, Il4r, Nfkbie, Il6, Stat3, Nfkb2, Fcgr2b, Il1r2, Hmox1, Nfkbia, Il1rn, Cd14,
Lbp, Nfkbib











Hspb3, Tnfrsf1a, Nfkbie, Il6, Nfkb2, Stat3, Cebpb, Jak2, Il1r2, Shc1, Nfkbia, Rras2,





Rac2, Icam1, Cxcl1, Pik3r5, Pgf, Eif4ebp1, Vegfa, Hmox1, Gng11, Gna13, Nfkbib,
Prkd1, Egfr, Vcam1, Rhoc, Rac1, Vegfc, Irak3, Cstb, Myl7, Myl9 (Includes
Eg:98,932), Bcl2l1, Itgb2, Rras2, Ccnd2, Itgam, Irak2




Fgf16, Mmp3, Fgf9, Mmp14, Mmp15, Vegfc, Pgf, Myc, Vegfa, Rras2, Mmp8, Fgf12,
Cdkn1a, Chd1 (Includes Eg:1105), Rps6Ka5, Fgf7, Egfr




Cxcl10, Ccr1, Cxcl9, Ccl5, Cxcl11

















C1R, Cfd, Serping1, C3, C1S, Cfb, C4a, Masp1, C2




Rac2, Icam1, Nfkbie, Pik3R5, Pbx1, Ccl5, Jak2, Il6, Fcgr1a, Nr3c1, Il1R2, Shc1, Cxcl3,
Hspa4, Nfkbia, Ar, Ccl13, Cdkn1c, Serpine1, Stat1, Fkbp5, Nfkbib, Sra1, Vcam1,
Ccnh, Sele, Rac1, Stat3, Cebpb, Bcl2l1, Rras2, Il1rn, Cdkn1a, Fkbp4, Nr3c2
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are discussed further in the online Supplementary
material.
A2AR modulation of the endotoxemic transcriptome
Despite well-established anti-inflammatory effects of
acute A2AR agonism, the myocardial transcriptomic re-
sponse to endotoxemia was largely insensitive to A2AR
KO (Figs. 3 and 4; Tables 7 and S9). Rather than a
broadly suppressive impact of A2AR activity, only
10 % of the transcriptomic response was modified by
KO. This selective outcome is consistent with data for
cytokine/chemokine transcription and release—the ma-
jority of these responses were also unaltered by A2AR
deletion, which specifically modified Il6, Cxcl2, Cxcl5
and Csf3 induction (Fig. 4) and circulating IL-5, hapto-
globin and CRP levels (Figs. 1 and 2). These responses
are nonetheless relevant to myocardial outcome: IL-6
initiates and expands inflammatory signalling, and
CXCL2 and CXCL5 both participate in cardiac inflam-
mation and remodelling. Important IL-6 target genes
were highly induced with LPS, including Bcl2l1,
Cebpb, Irf1, JunB, Lbp, Socs3 and Timp1. By suppress-
ing IL-6 transcription, potentially through IκBζ induc-
tion and STAT1 repression, A2AR activity may limit
cardiac IL-6 signalling. Functional annotation of A2AR
sensitive transcripts does support modulation of acute
phase response, JAK-STAT, MAPK, PRR and NFκB
pathways (Tables 7, S6 and S10). Figure 6 summarizes
these key changes, highlighting impacts of A2AR KO.
Through modifying a small number of key transcript
responses (Nfkbie, Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and
Rras2), A2AR activity may limit expansion of injurious
inflammation in endotoxemic myocardium. In contrast,
the cardio-depressant molecular profile appears insensi-
tive to A2AR KO.
NFκB signalling The A2AR represses NFκB signalling via
multiple mechanisms in non-cardiac cells, including phos-
phorylation-/SUMOylation-dependent IκB degradation and
modulation of the SCF-E3 ubiquitin ligase complex [58].
The absence of A2ARs did modify the NFκB path in
endotoxemic myocardium (Fig. 6), amplifying pro-
inflammatoryNfkbiz (IκBζ) induction while countering inhib-
itory Nfkbie (IκBε) induction. Enhanced transcription of IκBζ
and its targets Lcn2 and Il6 with A2AR KO suggests the re-
ceptor may suppress inflammation by inhibiting IκBζ induc-
tion and its transcriptional actions, while promoting IκBε in-
duction to limit nuclear translocation of NFκB (Fig. 6).
In contrast, A2AR KO also reduced induction of mole-
cules promoting NFκB signalling (Fig. 6): Eif2ak2/Pkr
inhibits IκBα expression and enhances NFκB signaling
and IFN-β expression; Btrc promotes degradation of
IκBα and Rac2 promotes cytokine-triggered NFκB
signalling and IFN-γ expression. It is unclear what the
balance of these changes might be, though repression
Fig. 6 Schematic of TLR, IL-1,
IL-6 and interferon receptor
activation of NFκB and JAK-
STAT signalling and
transcriptional control. The
effects of A2AR KO- on LPS-
dependent gene changes are
highlighted. These pathways are
critical to cellular responses to
LPS and orchestration of
inflammation. Specific effects of
A2AR activity (based on effects of
receptor KO) on transcriptional
responses to LPS are highlighted
(red—increased expression;
blue—reduced expression)
Fig. 5 Impact of 24 h LPS challenge on cardiac transcription of the TLR
(upper panel) and interferon signalling paths (lower panel) in wild-type
mice (n = 6–8/group). Induced transcripts highlighted in red and
repressed in green. Shaded transcripts are altered by LPS by less than
the threshold value
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Table 6 Top canonical responses to LPS modified by A2AAR KO (the 15 most promoted or inhibited by A2AAR KO are shown)
Canonical Pathways P value Ratio Genes
LPS responses enhanced by A2AR KO (countered by A2AR activity)




Hpx, Hp, Rras2, Pik3r1, Cp, Il6, Serpine1, Nr3c1, Orm1




Hspa4, Cxcl3, Rras2, Pik3r1, Cdkn1a, Tgfb2, Il6, Stat1, Serpine1, Hspa2,
Nr3c1




Timp4, Rras2, Pik3r1, Rhoj, Itgb3














Ppp2r3a, Pik3r1, Vegfc, Atf4, Rhoj, Itgb6, Pgf, Itgb3









Rras2, Pak6, Pak3, Ppp2r3a, Ppp1R3c, Pik3r1, Atf4, Stat1




Pik3r1, Cdkn1a, Tgfb2, Vegfc, Stat1, Pgf




Rras2, Pik3r1, Cdkn1a, Itgb6, Itgb3




Map3k6, Ppp2r3a, Ppp1r3c, Pik3r1, Rhoj, Irf8, Stat1




Cxcl3, Tgfb2, Vegfc, Il6, Stat1, Pgf














Rras2, Pik3r1, Cdkn1a, Stat1
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
PXR/RXR activation 6.46E-
04
4.4E-02 Rac2, Prkar2b, Cyp2b6



















Rac2, Prkar2b, Adipoq, Eif4ebp1









Rac2, Nfkbie, Btrc, Eif2ak2










































Canonical pathways modified by LPS, ranked according to P-values determined by Fisher’s Exact Test. Also shown is the ratio reflecting the number of
molecules in a given path that meet cut-off criteria for differential expression, divided by the total number of molecules in the path
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of the distal transcriptional effector IκBζ is predicted to
limit effects of up-stream changes. Failure of A2AR KO to
modify changes in genes recently implicated in
cardioprotective effects of NFκB signalling [47] (includ-
ing induction of Ptx3, Plscr1, Sfi1 and Igfbp3 and repres-
sion of Car3, Dkk3, ai605517 and Grhl2) suggests
receptor activity might selectively modify injurious rather
than protective aspects of NFκB signalling.
JAK-STAT signalling In non-cardiac cells, A2AR agonism
also inhibits JAK-STAT signalling, via control of SOCS tran-
scription [58] and ubiquitination/degradation of JAK-
Table 7 Functional groupings of
genes for which LPS responses
were modified by ≥1.5-fold
(induction or repression) by A2AR
KO
Functional grouping P value Number of genes
LPS responses enhanced by A2AR KO (countered by A2AR activity)
Molecular and cellular functions
Cellular Movement 1.10E-08–5.10E-03 58
Cell-To-Cell Signalling and Interaction 1.78E-06–5.40E-03 46
Cell Death 1.13E-05–4.87E-03 74
Cellular Growth and Proliferation 1.30E-05–5.40E-03 58
Cell Cycle 2.22E-05–4.86E-03 30
Physiological system development and function
Haematological System Development and Function 3.17E-07–5.40E-03 53
Haematopoiesis 3.17E-07–4.79E-03 36
Tissue Morphology 3.17E-07–4.79E-03 38
Immune Cell Trafficking 3.90E-07–5.10E-03 37
Cardiovascular System Development and Function 1.54E-06–4.25E-03 24
Disease and disorders
Cancer 3.71E-08–5.03E-03 82
Immunological Disease 9.17E-08–3.81E-03 72
Skeletal and Muscular Disorders 7.90E-07–3.81E-03 77
Inflammatory Response 1.78E-06–5.05E-03 46
Haematological Disease 2.44E-06–3.68E-03 37
LPS responses inhibited by A2AR KO (promoted by A2AR activity)
Molecular and cellular functions
Carbohydrate Metabolism 2.24E-05–2.33E-02 6
Molecular Transport 2.38E-05–2.61E-02 24
Small Molecule Biochemistry 2.38E-05–2.87E-02 34
Lipid Metabolism 4.28E-05–2.87E-02 14
Cellular Compromise 6.16E-05–2.61E-02 11
Physiological system development and function
Cardiovascular System Development and Function 4.28E-05–2.97E-02 5
Organ Development 4.28E-05–2.33E-02 7
Organismal Functions 9.49E-05–2.61E-02 4
Haematological System Development and Function 2.54E-04–3.11E-02 13
Lymphoid Tissue Structure and Development 2.54E-04–2.61E-02 6
Disease and disorders
Inflammatory Response 6.16E-05–3.11E-02 15
Nutritional Disease 8.22E-05–6.58E-03 10
Genetic Disorder 1.34E-04–3.00E-02 30
Developmental Disorder 2.54E-04–2.61E-02 14
Neurological Disease 2.54E-04–2.61E-02 30
Functional groupings of LPS-responsive cardiac transcripts modified by A2AR KO (enhanced or repressed) by a
factor of ≥1.5-fold. Functional groups derived from IPA analysis are categorized into molecular and cellular
functions, physiological system development and function, and disease and disorders, and ranked according to
P value ranges determined by a Fisher’s Exact Test. Total numbers of involved genes are also shown
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phosphorylated STATs [87]. Despite no evidence for A2AR
modulation of Socs3 (induced with LPS unaltered by KO),
A2AR deletion did modify the JAK-STAT response, exagger-
ating induction of both Stat1 and the key activator Il6. Since
STAT1 is crucial to LPS-induced apoptosis in non-cardiac
cells [88], and mediates injury with ischemic insult [39],
A2AR-dependent suppression is predicted to be protective.
Deletion of A2ARs also enhanced endotoxemic induction of
Cdkn1a/p21Cip1/Waf1 (modulator of STAT1-dependent apo-
ptosis and IFN-γ/STAT signalling, linked to poor sepsis out-
comes [49]) and the signal transducer Rras2. These data col-
lectively support beneficial A2AR modulation of JAK-STAT
activation in endotoxemic myocardium (Fig. 6).
Select impacts on acute phase response vs. TLR and inter-
feron signalling The acute phase response is triggered by
IL-1, IL-6 and TNF-α and transduced via NFκΒ and
JAK-STAT signals. Additional to effects of KO on Il6
and JAK-STAT and NFκB paths, A2AR activity appears
to counter induction of key gene targets (Serpine1, Il6,
Cp, Hpx, Hp and Orm1). Conversely, A2AR activity was
also associated with greater induction of target genes C3
and Hmox and reduced induction of the glucocorticoid
receptor inhibiting this inflammatory response. While
mixed, collective shifts in JAK-STAT/NFκB paths sup-
port transcriptional suppression of the acute phase re-
sponse via A2AR activity. However, while TLR/
interferon paths were among the most highly responsive
to LPS, A2AR KO did not substantially modify these
responses (augmenting induction of MyD88-responsive
Irf8 and altering downstream NFκB signalling). Major
changes in interferon signalling were also largely un-
modified by A2AR KO (Fig. 6), suggesting select im-
pacts of A2AR activity on elements of the acute phase
response yet not associated TLR and interferon
signalling.
Novel effects of A2AR KO The impact of A2AR activity is
limited primarily to canonical elements of endotoxemia
(Tables 6, S10 and S11); however, several of the more
A2AR-sensitive transcriptional responses to LPS hint at novel
effects of A2AR signalling, including modulation of insulin-
sensitivity, hypertrophic growth/remodelling and cardiac
rhythmicity, together with influencing angiogenesis and vas-
cular control.
Disruption of insulin-dependent glucose metabolism is an
important consequence of endotoxemia, and three of the most
A2AR-sensitive transcripts (Ptprf, Glut4/Slc2a4 and Glut12/
Slc2a12) govern insulin-dependent glucose uptake
(Table S9). Endotoxemic suppression of Glut4 and the sec-
ondary insulin-sensitive transporter Glut12 and the induction
of Ptprf (encoding protein tyrosine phosphatase, receptor type
F; implicated in insulin-resistance) were exaggerated >two-
fold with A2AR KO (Table S9). Endotoxemic suppression of
Glut4 and glucose uptake is reported in skeletal and cardiac
muscle [89]. Conversely, increased expression of Glut4 im-
proves glucose uptake and limits myocardial dysfunction in
endotoxemia [89]. These responses to A2AR KO suggest reg-
ulatory influences of A2AR activity on glucose handling in
endotoxemic tissue.
Other highly A2AR-sensitive transcriptional responses
suggest A2AR modulation of myocardial remodelling, in-
cluding shifts in Asb14 and Asb15, Ca3 and Ca4 and
Dnmt3a and Srpk2. Endotoxemic repression of transcripts
for 2 ankyrin repeat and SOCS box (ASB) proteins,
Asb14 and Asb15, was substantially exaggerated with
A2AR KO. The ASB family bind and target proteins for
degradation and regulate skeletal muscle development,
while roles in heart are unclear. The ASB15 protein en-
hances skeletal muscle protein synthesis [90] and delays
differentiation, potentially via modulating MAPK and
PI3K/Akt signalling [91]. This control may be important
in adaptive response to muscle load/activity. Carbonic
anhydrases are also implicated in myocardial hypertrophy,
with endotoxemic Car4 induction (the dominant cardiac
isoform) exaggerated and Car3 downregulation was
inhibited in A2AR KO hearts. The myocardial roles of
these enzymes are only beginning to be unravelled,
though they may promote hypertrophic responses by fa-
cilitating Na+-H+ and Cl-HCO3 exchanger over-activities,
while evidence from other cells suggests CAR3 may mod-
ify oxidative stress and apoptosis. Similarly, Srpk2 induc-
tion was augmented in the absence of A2ARs, encoding a
serine/arginine (SR) protein kinase (SRPK) that phosphor-
y l a t e s SR doma in - con t a i n i ng p ro t e i n s w i t h i n
interchromatin granule clusters/nuclear speckles to regu-
late pre-mRNA splicing. The SRPK2 protein also plays an
Fig. 7 Comparison of expression values for select transcripts assessed
via array analysis and quantitative real-time PCR. Expression ratios are
relative to values in wild-type (WT) hearts treated with normal saline
(NS) and are thus shown for WTs treated with LPS for 24 h (WT LPS)
and A2AR KO hearts untreated (KO NS) or treated with LPS (KO LPS).
Data are means ± S.E.M, n = 6–8/group
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important role in cell proliferation and apoptosis.
Additionally, downregulation of the methyltransferase
transcript Dnmt3a, governing growth and function of em-
bryonic myocytes [92], appears to be countered by A2AR
activity, which may also limit cardiac fibrosis/remodelling
[93]. Collectively, this suite of A2AR responsive changes
may limit myocardial hypertrophy and remodelling re-
sponses to inflammatory insult. This is consistent with
functional groupings sensitive to A2AR KO, including de-
terminants of cell cycle, growth, proliferation and death
and cardiovascular development (Table 7) and shifts in
canonical hypertrophy pathways (Tables S10 and S11).
Curiously, A2AR activity also limited LPS induction of
Hcn1 (Table S9). The HCN proteins mediate the pacemaker
(funny) current governing cardiac automaticity/excitability.
While HCN4 is the most highly expressed, HCN1 is signifi-
cantly expressed within the conduction network, contributes
to cardiac rhythmicity [94] and is up-regulated in hypertrophy
and heart failure. Endotoxemic induction may thus promote
arrhythmicity, while A2AR activity appears to suppress this
change.
Finally, A2AR KO modified a broader range of vas-
cular control and growth pathways in endotoxemic (vs.
healthy) hearts. Vascular dysfunction is a critical to or-
gan damage and mortality and may involve NOS over-
activity in some vascular beds. Deletion of the A2AR
modified NO signalling together with renin-angiotensin
signalling (Table S10), while cardiac arteriopathy was
identified as a pathological process sensitive to KO
(Table S11). These responses support influences of
A2AR signalling on vascular pathology. We have previ-
ously shown endotoxemia impairs coronary hyperaemia,
a dysfunction mimicked by KO of (and potentially in-
volving) the A2AR [23]. Additionally, there is an appar-
ent coronary ‘over-supply’ relative to myocardial de-
mand in endotoxemic hearts (Table 1), owing to 25–
30 % lower contractile function without reductions in
coronary perfusion. The absence of coronary coupling
to ventricular activity, described by us in this and other
models [95, 96], suggests additional coronary dysregu-
lation (though this effect is neither replicated nor mod-
ified by A2AR KO). Multiple paths/mediators regulating
angiogenesis were also sensitive to A2AR KO in
endotoxemic heart, including shifts in VEGF, HIF-1α,
angiopoietin, TGF-β, GM-CSF, PDGF and IGF-1 path-
ways (Table S10) and key regulatory molecules (includ-
ing exaggerated induction of Il6, Pgf, Tgfb2, Tgfb2r,
Angptl4 and Amotl1; exaggerated suppression of Vegfc
and reduced suppression of Qk) (Table S9). While the
A2B receptor is more broadly implicated in control of
angiogenesis, these changes suggest A2AR-dependent
processes may influence angiogenesis in the context of
uncontrolled inflammation.
RT-qPCR confirmation of microarray-detected responses
Data confirm agreement between transcript expression de-
termined via RT-qPCR and microarray methods (Fig. 7),
with PCR further highlighting distinct transcriptional ef-
fects of A2AR KO: in some cases, KO eliminates re-
sponses to LPS (Acta1); alters baseline yet not LPS-
dependent expression (Amid or Dbp); enhances induction
(Txnip) or repression (Cidec) in response to vehicle and
LPS or reduces gene expression in the vehicle group
while negating further changes with LPS (Eif4ebp2 and
Slc38a1). Confirming the microarray approach, some of
these responses are also functionally relevant. For exam-
ple, Txnip encodes a stress-responsive protein inhibiting
the anti-oxidant/signalling molecule thioredoxin.
Reductions in TXNIP inhibit vascular inflammation and
TNF-α signalling [97], TXNIP dysregulation promotes in-
flammatory disease [98] and elevations in TXNIP facili-
tate apoptosis [99]. Inhibition of Txnip induction by A2AR
activity may thus enhance protective thioredoxin
functionality.
Study limitations
Several study limitations are worth noting. While essential
genesis of cardiac injury is studied and understood within
the in situ organ, this entails experimental limitations in-
herent to in vivo studies of organ dysfunction in sepsis/
endotoxemia [15, 16, 20, 21, 24, 41, 42, 49]. Organ injury
in these settings not only involves intrinsic organ-specific
mechanisms but also influenced by extrinsic factors, in-
cluding shifts in systemic inflammation, haemodynamics
and neuroendocrine influences (with relative impacts of
these factors difficult to delineate). Although we assess
the intrinsic myocardial dysfunction in ex vivo tissue (to-
gether with in vivo markers of cardiac damage), we can-
not isolate potential influences of A2AR KO on cardiac
loading, neurohumoral factors or indeed systemic inflam-
mation. That said, while A2AR KO augmented some in-
flammatory markers, systemic and cardiac cytokine re-
sponses were largely insensitive to KO and the myocardi-
al response was very selectively modified, indicating dis-
tinct effects of A2AR activity on cardiac injury processes.
We are also unable to detail cell-specific origins of myo-
cardial transcriptional changes. Migrating inflammatory
cells could influence the transcriptomic profile for intact
myocardium, though, as detailed in the Supplementary
material, the expression profile of endotoxemic myocardi-
al tissue is inconsistent with major contamination from
such cells. An added limitation relates to the intriguing
observation of both age- and sex-dependent mortality ef-
fects of LPS and A2ARs (Fig. S3). This unfortunately
precluded any detailed interrogation of these outcomes
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due to poor survival in older KO mice. Future work might
focus specifically on responses to LPS/sepsis in clinically
relevant aged cohorts, correlating age-dependent
transcriptomic and phenotypic outcomes. Finally, while
profound transcriptional changes observed in the current
profiling study are predicted to translate to functionally
relevant protein changes, this exploratory analysis does
not directly confirm altered protein expression.
Conclusions
Deletion of the A2AR induces modest effects in healthy myocar-
dium, shifting transcription of G protein coupled cAMP/PKA,
MEKK2 and cGMP/NO signalling downstream of this and oth-
er GPCRs, without impacting cardiac function. However, the
receptor may play a retaliatory role in selectively suppressing
inflammatory signalling and injury, yet, not contractile depres-
sion, in endotoxemicmyocardium. Cardiac endotoxemia itself is
characterized by profound upregulation of acute-phase response,
PRR/TLR and interferon signalling and cell death and remodel-
ling pathways, together with broad suppression of primary de-
terminants of contractility (Ca2+, ß-adrenergic and PKA signal-
ling; mitochondrial function; electromechanical coupling) and
induction of cardio-depressant genes (Lcn2, S100a8/S100a9,
Icam1, Vcam1,Nox2,Cox2, Tnfr1 and Fas). This complex tran-
scriptome is selectively A2AR sensitive, with effects of KO im-
plicating modulation of key regulatory molecules (Nfkbie,
Nfkbiz, Il6, Lcn2, Stat1, Cdkn1a and Rras2) to suppress myo-
cardial JAK-STAT/NFκB and pro-inflammatory IL-6 and TLR
signalling, togetherwith influencing determinants of insulin-sen-
sitivity, hypertrophy/remodelling and vascular function/angio-
genesis. In contrast, endotoxemic suppression of β-adrenergic,
PKA, Ca2+ signalling, electromechanical and mitochondrial
function pathways appears insensitive to A2AR KO, as does
contractile dysfunction itself.
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